Quanterix Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report; quarterly results are not clearly provided in the supplied text. Amounts below are in U.S. dollars.
Business context
Quanterix develops and sells ultra-sensitive Simoa protein-detection platforms, assays and consumables, and contract research services. Its principal markets are life-sciences research and drug trials; clinical diagnostics and precision-health screening remain longer-term opportunities. The installed instrument base grew 32% to 708 at year-end. Consumables represented about 50% of 2021 revenue.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $110.6 million | $86.4 million |
| Product revenue | $81.1 million | $44.0 million |
| Instrument revenue | $26.0 million | $16.6 million |
| Consumables and other product revenue | $55.1 million | $27.4 million |
| Service and other revenue | $23.6 million | $24.1 million |
| Collaboration and license revenue | $0.6 million | $11.8 million |
| Grant revenue | $5.2 million | $6.4 million |
| Gross profit / gross margin | $61.7 million / 55.8% | $48.2 million / 55.8% |
| Operating expenses | $120.3 million | $79.8 million |
| Operating loss | $58.6 million | $31.6 million |
| Net loss | $57.7 million | $31.5 million |
| Cash used in operating activities | $47.9 million | $23.4 million |
| Cash and cash equivalents at year-end | $396.5 million | $181.6 million |
Revenue increased 28%, mainly as customer sites reopened and instrument installations and consumables sales recovered. Product revenue rose 84%; consumables revenue more than doubled as the installed base expanded. The year-over-year decline in licensing revenue largely reflects the $10.0 million Abbott upfront license fee recognized in 2020. Gross margin was essentially unchanged, while operating expenses rose 51%, primarily from staffing and investment in growth, contributing to the larger loss. Basic and diluted net loss per share was $1.60, versus $1.07 in 2020.
Operating cash use increased to $47.9 million, with higher inventory and receivables also using cash. Investing activities used $6.3 million, including $13.6 million of property and equipment purchases partly offset by $7.3 million of grant proceeds for assets. Financing provided $270.8 million, primarily from the February 2021 stock offering, which generated $269.7 million net. Quanterix repaid its remaining term loan, including end-of-term fees, in October 2021; no debt remained at year-end. Total liabilities were $60.6 million, including lease liabilities.
Year-end stockholders’ equity was $441.0 million and accumulated deficit was $305.5 million. Shares outstanding increased from 31.8 million to 36.8 million during 2021, primarily reflecting the public offering and equity compensation. Management said existing cash and commercial receipts should fund operations for at least 12 months; it also expected operating losses to continue for at least the next 24 months.
Material changes, outlook and risks
- COVID-19 and diagnostics: The FDA issued EUAs for the Simoa SARS-CoV-2 IgG antibody test and N-protein antigen test; the antigen test authorization was expanded in September 2021. EUAs are emergency authorizations, not standard marketing approvals, and may be revised or revoked. NIH RADx awards supported test development and scale-up; $17.7 million of the $18.2 million WP2 award had been received by year-end, with one milestone extended to March 31, 2022.
- Potential Alzheimer’s test: The pTau-181 assay received FDA Breakthrough Device designation as an aid in diagnostic evaluation. The filing describes this as an opportunity, not an approval or clearance; management aimed to launch its first laboratory-developed test in 2023.
- Commercial and execution risks: Nf-L and other neurological assays are increasingly important to revenue. Adoption, competition, instrument sales cycles, and customer research budgets could affect growth. HD-X and SR-X manufacturing and some consumables rely on single or limited-source suppliers.
- Regulatory and reimbursement exposure: Most products are labeled for research use only. Broader diagnostic use may require costly, lengthy regulatory clearance or approval and reimbursement; evolving regulation of laboratory-developed tests could add uncertainty.
- Other financial and operational risks: The company reported recurring losses and higher cash burn, and stated it may need additional financing if requirements exceed available resources. One customer represented 18% of year-end gross receivables, and one customer accounted for 14% of fourth-quarter revenue. Inventory demand estimates were identified by the auditor as a critical audit matter.
- Unusual item: Quanterix recorded $2.1 million related to an employee retention tax credit; it reported the expected refund as a current asset at year-end. Other income also included foreign-exchange effects.
- Expansion and governance: In January 2022, the company signed an eight-year-nine-month lease for approximately 85,800 square feet in Bedford, Massachusetts. Management and the auditor reported effective internal controls over financial reporting as of December 31, 2021. The company reported no material pending legal proceedings.
No specific revenue or earnings guidance is provided in the supplied filing text. Management expects continued investment in sales, research and development, staffing, and product expansion, and notes that the length and severity of the pandemic remain uncertain.
Important facts for investors to verify
- Whether recurring consumables growth and instrument placements can sustain revenue growth as COVID-related activity and customer reopening effects change.
- Cash-burn trajectory and funding runway against management’s stated outlook, including the cost of expansion and new product development.
- How much future revenue depends on Nf-L/neurology, grants, COVID-19 testing, or other concentrated products and customers.
- Regulatory progress, reimbursement prospects, and commercial timing for pTau-181 and other diagnostic opportunities; Breakthrough designation does not assure approval.
- Inventory levels and demand assumptions, accounts-receivable concentration, and exposure to sole-source manufacturers and suppliers.
- The dilution implications of equity compensation and future financing needs; 2021 financing included a substantial public stock offering.